ACM
APLS

Atika Capital Management’s Apellis Pharmaceuticals APLS Stock Holding History

Atika Capital Management’s Portfolio APLS Stock Details APLS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-186,500
Closed -$12.7M – 68
2022
Q3 		$12.7M Buy
186,500
+76,500
+70% +$4.53M 1.08% 38
2022
Q2 		$4.97M Buy
+110,000
New +$5.02M 0.56% 53

Other funds holding APLS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Atika Capital Management's APLS Position: Q4 2022 in Review

Atika Capital Management sold out of Apellis Pharmaceuticals (APLS) in Q4 2022, closing a stake of 186,500 shares — an estimated $12.7M sold.

Atika Capital Management first reported a position in APLS in Q2 2022 and held it in 2 quarters. The position peaked at $12.7M in Q3 2022. 244 funds tracked by Wall St. Rank hold APLS as of Q4 2022.

  • Atika Capital Management reported no remaining Apellis Pharmaceuticals position as of Q4 2022 after selling out during the quarter.
  • Atika Capital Management sold 186,500 Apellis Pharmaceuticals shares in Q4 2022, an estimated $12.7M.
  • Atika Capital Management first reported a position in Apellis Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • Atika Capital Management's Apellis Pharmaceuticals position peaked at $12.7M in Q3 2022.
  • 244 funds tracked by Wall St. Rank held Apellis Pharmaceuticals as of Q4 2022.

Based on Atika Capital Management's 13F filing for Q4 2022, filed 13 Feb 2023.